PropThink: NAVB Re-Submits Lymphoseek NDA; Approval Could Come Soon

[ACN Newswire] – By David MoskowitzNavidea Biopharmaceuticals (NASDAQ:NAVB) announced that on October 30th it resubmitted its new drug application (NDA) for Lymphoseek in response to the FDA’s Complete Response Letter … more

View todays social media effects on CAH

View the latest stocks trending across Twitter. Click to view dashboard